[go: up one dir, main page]

AU2001259846A1 - Methods and compositions for enhancing the delivery of a nucleic acid to a cell - Google Patents

Methods and compositions for enhancing the delivery of a nucleic acid to a cell

Info

Publication number
AU2001259846A1
AU2001259846A1 AU2001259846A AU5984601A AU2001259846A1 AU 2001259846 A1 AU2001259846 A1 AU 2001259846A1 AU 2001259846 A AU2001259846 A AU 2001259846A AU 5984601 A AU5984601 A AU 5984601A AU 2001259846 A1 AU2001259846 A1 AU 2001259846A1
Authority
AU
Australia
Prior art keywords
enhancing
delivery
compositions
cell
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001259846A
Inventor
Peter L. Jones
Robert J Levy
Quanyi Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital of Philadelphia CHOP
Original Assignee
Childrens Hospital of Philadelphia CHOP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital of Philadelphia CHOP filed Critical Childrens Hospital of Philadelphia CHOP
Publication of AU2001259846A1 publication Critical patent/AU2001259846A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001259846A 2000-05-22 2001-05-10 Methods and compositions for enhancing the delivery of a nucleic acid to a cell Abandoned AU2001259846A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20614300P 2000-05-22 2000-05-22
US60/206,143 2000-05-22
PCT/US2001/040706 WO2001090345A2 (en) 2000-05-22 2001-05-10 Methods and compositions for enhancing the delivery of a nucleic acid to a cell

Publications (1)

Publication Number Publication Date
AU2001259846A1 true AU2001259846A1 (en) 2001-12-03

Family

ID=22765153

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001259846A Abandoned AU2001259846A1 (en) 2000-05-22 2001-05-10 Methods and compositions for enhancing the delivery of a nucleic acid to a cell

Country Status (5)

Country Link
US (2) US6919208B2 (en)
JP (1) JP2004530401A (en)
AU (1) AU2001259846A1 (en)
CA (1) CA2410827A1 (en)
WO (1) WO2001090345A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191275A1 (en) * 1998-07-30 2007-08-16 Regenerx Biopharmaceuticals, Inc. Method of treating, preventing, inhibiting or reducing damage to cardiac tissue with thymosin beta 4 fragments
US20060100156A1 (en) * 2004-10-01 2006-05-11 Regenerx Biopharmaceuticals, Inc. Cell nucleus-entering compositions
JP2008511678A (en) * 2004-09-02 2008-04-17 イェール ユニバーシティ Regulation of oncogene by microRNA
CA2607701A1 (en) * 2005-05-27 2006-12-07 Regenerx Biopharmaceuticals, Inc. Cell nucleus-entering compositions
US8354384B2 (en) * 2005-06-23 2013-01-15 Yale University Anti-aging micrornas
US8658608B2 (en) * 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
WO2008086529A2 (en) * 2007-01-11 2008-07-17 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
US20100111943A1 (en) * 2007-03-22 2010-05-06 Medical College Of Georgia Research Institute, Inc Compositions and methods for inhibiting cancer metastasis
EP2257626A2 (en) * 2008-03-01 2010-12-08 Abraxis BioScience, LLC Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
CA2723716A1 (en) * 2008-05-07 2009-11-12 Abraxis Bioscience, Llc Enhancement of drug therapy by mirna
US8309356B2 (en) * 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
WO2011133802A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
WO2011133803A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for targeted inactivation of hiv cell surface receptors
WO2013044116A1 (en) 2011-09-21 2013-03-28 Yale University Antimicrobial compositions and methods of use thereof
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
EP4331618A3 (en) 2014-05-09 2024-06-12 Yale University Hyperbranched polyglycerol-coated particles and methods of making and using thereof
US20170216363A1 (en) 2014-08-07 2017-08-03 The Johns Hopkins University Nanoparticle modification of human adipose-derived mesenchymal stem cells for treating brain cancer and other neurological diseases
AU2017221424A1 (en) 2016-02-16 2018-09-20 Yale University Compositions and methods for treatment of cystic fibrosis
EP3416976A2 (en) 2016-02-16 2018-12-26 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
JP7570106B2 (en) 2018-08-31 2024-10-21 イェール ユニバーシティー Compositions and methods for enhancing triplex and nuclease-based gene editing
KR20210053930A (en) 2018-08-31 2021-05-12 예일 유니버시티 Compositions and methods for enhancing donor oligonucleotide-based gene editing
EP3867365A1 (en) 2018-10-19 2021-08-25 Board of Regents, The University of Texas System Engineered long interspersed element (line) transposons and methods of use thereof
WO2020257779A1 (en) 2019-06-21 2020-12-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
US20220243211A1 (en) 2019-06-21 2022-08-04 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
WO2021022161A1 (en) 2019-07-31 2021-02-04 Yale University Compositions and methods for treating sickle cell disease
AU2020336992A1 (en) 2019-08-30 2022-04-14 Yale University Compositions and methods for delivery of nucleic acids to cells
KR20230079367A (en) 2020-08-31 2023-06-07 예일 유니버시티 Compositions and methods for delivering nucleic acids to cells
EP4352226A1 (en) 2021-06-07 2024-04-17 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
AU2023361162A1 (en) 2022-10-11 2025-05-29 Yale University Compositions and methods of using cell-penetrating antibodies
WO2024263649A1 (en) 2023-06-19 2024-12-26 Yale University Methods and compositions for enrichment and sequencing of expansion-specific rna transcripts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2193954A1 (en) * 1994-06-27 1996-01-04 Vu L. Truong Targeted gene delivery system
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US5849902A (en) * 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
JP2002500201A (en) 1998-01-05 2002-01-08 ユニバーシティ オブ ワシントン Enhanced transport using membrane disruptors
US7737108B1 (en) 2000-01-07 2010-06-15 University Of Washington Enhanced transport using membrane disruptive agents

Also Published As

Publication number Publication date
WO2001090345A2 (en) 2001-11-29
CA2410827A1 (en) 2001-11-29
US6919208B2 (en) 2005-07-19
WO2001090345A3 (en) 2002-11-28
US20050080030A1 (en) 2005-04-14
JP2004530401A (en) 2004-10-07
US20020034821A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
AU2001259846A1 (en) Methods and compositions for enhancing the delivery of a nucleic acid to a cell
AU2002318944A1 (en) Methods and compositions relating to plasmacytoid dendritic cells
AU2001292842A1 (en) Compositions and methods relating to prostate specific genes and proteins
AU2002245184A1 (en) Nucleic acid amplification
AU2002249787A1 (en) Compositions and methods relating to lung specific genes and proteins
AU5832100A (en) Composition to be used in paints
AU2002219988A1 (en) Compositions and methods relating to breast specific genes and proteins
AU2002245031A1 (en) Compositions and methods relating to prostate specific genes and proteins
AU2002220009A1 (en) Compositions and methods relating to lung specific genes and proteins
AU2001286810A1 (en) Compositions and methods relating to lung specific genes
AU2001297741A1 (en) Compositions and methods relating to breast specific genes and proteins
AU2001253001A1 (en) Non-pcr based recombination of nucleic acids
AU2001274954A1 (en) Compositions and methods for delivery of a molecule into a cell
AU2002239409A1 (en) Compositions and methods relating to colon specific genes and proteins
AU2002217991A1 (en) Compositions and methods relating to prostate specific genes and proteins
AU2001277937A1 (en) Compositions and methods relating to lung specific genes
AU2001266189A1 (en) Materials and methods relating to gene delivery
AU2002364968A1 (en) Compositions and methods relating to hepatic specific genes and proteins
AU2001260313A1 (en) Compositions and methods for nucleic acid analyses
AU2001297804A1 (en) Compositions and methods relating to breast specific genes and proteins
AU2002241557A1 (en) Compositions and methods relating to prostate specific genes and proteins
AU5658301A (en) A particulate complex for administering nucleic acid into a cell
AU2002236534A1 (en) Compositions and methods relating to ovary specific genes and proteins
AU2002241730A1 (en) Compositions and methods relating to lung specific genes and proteins
AU2002219819A1 (en) Compositions and methods relating to colon specific genes and proteins